Targeting Methylglyoxal in Diabetic Kidney Disease Using the Mitochondria-Targeted Compound MitoGamide

Targeting Methylglyoxal in Diabetic Kidney Disease Using the Mitochondria-Targeted Compound MitoGamide

Diabetic kidney disease (DKD) remains the number one cause of end-stage renal disease in the western world. In experimental diabetes, mitochondrial dysfunction in the kidney precedes the development of DKD. Reactive 1,2-dicarbonyl compounds, such as methylglyoxal, are generated from sugars both endo...

Full description

Bibliographic Details
Main Authors: Sih Min Tan, Runa S. J. Lindblom, Mark Ziemann, Adrienne Laskowski, Cesare Granata, Matthew Snelson, Vicki Thallas-Bonke, Assam El-Osta, Carlos D. Baeza-Garza, Stuart T. Caldwell, Richard C. Hartley, Thomas Krieg, Mark E. Cooper, Michael P. Murphy, Melinda T. Coughlan
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Nutrients
Subjects:
sugar-derived products
methylglyoxal
dicarbonyl
diabetes
kidney
mitochondria
Online Access:https://www.mdpi.com/2072-6643/13/5/1457

Internet

https://www.mdpi.com/2072-6643/13/5/1457

Similar Items